Dissertation > Excellent graduate degree dissertation topics show

The Analysis of the M8000/3 Coder of the Lung Cancer Case in a Hospital Between 2006 to 2010

Author: YuXiaoBo
Tutor: GaoXiaoHong
School: Dalian Medical University
Course: Epidemiology and Biostatistics,
Keywords: lung cancer pathology code M8000/3
CLC: R734.2
Type: Master's thesis
Year: 2011
Downloads: 1
Quote: 0
Read: Download Dissertation


Objective: By exploring the feature of M8000/3 coder of the lung cancer case, find the reason of no definite pathological diagnosis basis, in order to provide references for a reasonable clinical diagnosis of the lung cancer and a targeted treatment.Methods: Extract the lung cancer patients’medical record information from the database of the medical record room of our hospital, including: (1)General: name, sex, age, marital status and etc; (2) Treatment: surgery, chemotherapy, radiotherapy, supportive care (Conservative treatment) and etc.; (3) Discharge conditions: including better, healed and death; (4) Diagnosis basis: including x ray, CT, ultrasound, immunological and biochemical, cytological and pathological examination of blood films and so on. The statistical analysis is based of the SPSS11.5 statistical software.Results:1. The total of 2064 cases of primary lung cancer patients were investigated, of which 1310 cases are male, 754 cases are female, and their average age is 66.62±12.34;2. From the analysis of the composition of coder in the lung case, we found the pathology coding which is not explicitly carcinoma (M8000/3) of the lung cancer cases accounted for 43.46%, which is nearly the half ot the total number of hospitalized patients with newly diagnosed primary lung cancer;3. The average age of M8000/3 coders is 71.33±11.71, and the average of coders with clear pathology is 63.00±11.57. The age difference of the two is statistically significant;4. The largest number of M8000/3 coders is treated in the Department of Respiratory Medicine, followed by is the oncology and thoracic surgery; The largest number of clear pathological coders is treated at the Thoracic Surgery, followed is admitted to medical oncology and Respiratory Medicine, which is statistically significant difference between the two;5. The highest percentage of M8000/3 corders chooses the conservative treatment, while those with clear pathology coding and surgical treatment of chemotherapy take the highest proportion. The difference between the two is statistically significant;6. The average hospital stay of M8000/3 coders is 15.85±13.58 days, for those with clear pathological code is 21.39±21.50 days. The statistical analysis showed a statistically significant difference between the two;7. The highest proportion of M8000/3 coders takes the imaging studies, followed by are the biological immunity and pathology and cytology of blood films. The highest proportion of clear pathological coders takes the pathology, which is 92.54% and far higher than other inspection basis.The statistical analysis showed the difference is statistically significant.Conclusion: The higher the age, the occupancy of Respiratory Medicine, conservative treatment, a shorter hospital stay of the patients with lung cancer, the higher possibility to be M8000/3 corders eventually. Therefore, in order to achieve specific pathological type of lung cancer for a reasonable treatment reference, the above-mentioned characteristics for lung cancer clinically patients should be taken relevant measures to increase the proportion of pathological diagnosis.

Related Dissertations

  1. The Clinical Research for the Effect of Iodine-125 Seeds Implanted in Advanced Bronchial Lung Cancer,R734.2
  2. Effects of 5-Aza-2-deoxycytidine on DNA Methylation and Expression of p16 and MGMT Gene in Lung Cancer Cell Line SPC-A-1,R734.2
  3. Methylation of p16 Gene in Plasma and Tissues from Non-small Cell Lung Cancer Patients, Demethylation and the Biological Behavior of Lung Cancer Cell and Transcription of p16 Gene,R734.2
  4. The Clinical Value of Detection of Serum TPS, CEA, CYFRA21-1, NSE for Diagnosis in Patients with Lung Cancer,R734.2
  5. Study on the Expression and Correlation of Metallothionein and Matrix Metalloproteinase-2 in Non-small Cell Lung Cancer,R734.2
  6. The Effect of RNA Interference-mediated ERCC1 Gene on the Chemo-treatment Sensitivity of NSCLC in Vitro,R734.2
  7. Non-small Cell Lung Cancer Analysis of 133 Cases of CVATS Lobectomy,R734.2
  8. Clinical Observation of Pemetrexed for Treating Advanced Non-small Cell Lung Cancer,R734.2
  9. Combined Detection of Tumor Markers in the Diagnosis and Treatment of Lung Cancer to Determine the Clinical Significance,R734.2
  10. Exploreing the Mechanism of Xieshifeiaifang Ii on Treating Lung Cancer with Pleura Effusion,R734.2
  11. Expression of Chemokine Receptor CCR5 in Human Non-small-cell Lung Cancer,R734.2
  12. Influences of Cisplatin on Expressions of P-glycoprotein in the Resistance Cells of in Lung Cancer Xenografts in the Mice,R734.2
  13. Clinical Research on Detecing of the Combined Survivin mRNA with Cytokeratin 19(ck19) mRNA in Peripheral Blood of Non-small Cell Lung Cancer,R734.2
  14. The in Vitro Study of Serum-free Culture Combined DDP Enriching Human Lung Cancer Stem Cells,R734.2
  15. The Investigation of Relationship between Therapeutic Effect and Prognosis and Changes of Peripheral Blood Vascular Endothelial Growth Factor and Metallothionein in Patients with Advanced Lung Cancer,R734.2
  16. The Molecular Biology of Rh-endostatin Plus Chemotherapy as Adjuvant Treatment for Non-small Lung Cancer,R734.2
  17. Effectiveness of Erlotinib as the Sennd-line Therapy in Patients with Advanced NSCLC,R734.2
  18. Enhancing Effect of Newcastle Disease Virus in Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer,R734.2
  19. Clinical Study of Endostar Combined with Pemetrexed for Advanced Non-small Cell Lung Cancer,R734.2
  20. Association of Expression of ERCC1/RRM1 with Survival and Resistance to Platinum Inpatients with Ⅰ-ⅢA NSCLC,R734.2

CLC: > Medicine, health > Oncology > Respiratory system tumors > Lung tumors
© 2012 www.DissertationTopic.Net  Mobile